{
    "symbol": "PSTV",
    "quarter": 2,
    "year": 2022,
    "date": "2022-07-21 19:55:25",
    "content": " Finally, we fill the cohort dose and volume is likely appropriate to move forward as a recommended Phase 2 dose to treat patients with small- to medium-sized tumors, whether that's in the current Phase 2 NIH-sponsored trial that's ongoing, or combined Phase 2 or Phase 2/3 trial design sponsored by the Company that will be up to our discussions with the FDA. And then the trial design incorporates at that point, and this was a great suggestion by the FDA to come back to the FDA, and then we will amend -- based on the safety data, we'll amend the data collection and provide the opportunity for retreatment to these patients."
}